Cardiovascular adverse events complicating the administration of rituximab: Report of two cases

Tumori

Volumn 99, Issue 6, 2013, Pages

  Passalia, Caterina ^a   Minetto, Paola ^a   Arboscello, Eleonora ^a   Balleari, Enrico ^a   Bellodi, Andrea ^a   Del Corso, Lisette ^a   Molinari, Elisa ^a   Ponassi, Irene ^a   Oneto, Caterina ^a   Sicbaldi, Vera ^a   Ghio, Riccardo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cardiotoxicity; Cytokine; Lymphoma; Rituximab

Indexed keywords

CARVEDILOL; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVERSION; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; CASE REPORT; CHILL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATIONAL STUDY; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FEVER; HEART ATRIUM FIBRILLATION; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HEART RIGHT BUNDLE BRANCH BLOCK; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMOGLOBIN BLOOD LEVEL; HEPATOSPLENOMEGALY; HUMAN; HYPOTENSION; LEUKOCYTE COUNT; LYMPHADENOPATHY; LYMPHOCYTOSIS; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MITRAL VALVE REGURGITATION; MULTIPLE CYCLE TREATMENT; MYOCARDIAL PERFUSION IMAGING; TACHYCARDIA; THORAX PAIN; THROMBOCYTE COUNT; TRICUSPID VALVE REGURGITATION; TUMOR LYSIS SYNDROME; TUMOR VOLUME;

AGED; ANGINA PECTORIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RISK FACTORS; TUMOR BURDEN;

EID: 84894243774     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161309900622     Document Type: Article

References (20)

1. Pescovitz MD: Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant, 6: 859-866, 2006.
2. Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 63: 803-843, 2003. (Pubitemid 36432084)
3. Keating GM, Gillian M: Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs, 70: 1445-1476, 2010.
4. Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T: Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia, 16: 2004-2015, 2002. (Pubitemid 35203442)
5. Kharfan-Dabaja MA, Cutler CS: Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol, 93: 578-585, 2011.
6. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE: CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood, 95: 1502-1505, 2000 (Pubitemid 30099868)
7. Rigal D, Meyer F: Autoimmune haemolytic anemia: diagnosis strategy and new treatments. Transfus Clin Biol, 18: 277-285, 2011.
8. Vo KH, Waddell JA, Suda KJ: Rapid development of infusion-related severe hypotension during rituximab therapy. Ann Pharmacother, 45: e29, 2011.
9. Armitage JD, Montero C, Benner A, Armitage JO, Bociek G: Acute coronary syndromes complicating the first infusion of rituximab. Clin Lymphoma Myeloma, 8: 253-255, 2008.
10. Cervera Grau JM, Esquerdo Galiana G, Belso Candela A, Llorca Ferrándiz C, Juárez Marroquí A, Maciá Escalante S: Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin's diffuse large B-cell lymphoma. Clin Transl Oncol, 10: 298-299, 2008.
11. Arai Y, Tadokoro J, Mitani K: Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am J Hematol, 78: 316-319, 2005.
12. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol, 18: 317- 324, 2000.
13. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD: Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant, 4: 1357-1360, 2004. (Pubitemid 39013585)
14. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood, 94: 2217-2224, 1999. (Pubitemid 29467667)
15. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA: Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol, 17: 791-795, 1999. (Pubitemid 29109307)
16. Gulletta E, Foti DP, Galliera E, Corsi MM: Citochine e chemochine. Caleidoscopio 217, Editore: Medical Systems SpA, Genova, Giugno 2008.
17. Valgimigli M, Ferrari R, Masson S, Latini R: Scompenso cardiaco refrattario. Antagonismo del fattore di necrosi tumorale-alfa e dell'endotelina nell'uomo: due promesse da mantenere. Ital Heart J Suppl, 3: 793-803, 2002. (Pubitemid 37339254)
18. Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM: TNF-α and IL-1 increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium, 47: 378-386, 2010.
19. Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, Taniwaki M, Kano Y, Ohnishi K, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K; IDEC-C2B8 Study Group in Japan: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol, 13: 928-943, 2002. (Pubitemid 34752689)
20. Cartron G, Trappe RU, Solal-Céligny P, Hallek M: Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res, 17: 19-30, 2011.